摘要
重组人血小板生成素是高特异性的血小板刺激因子,直接作用于骨髓造血干细胞,调控血小板生成的各个阶段,特异性升高血小板。适用于实体瘤化疗后所致的血小板减少症,适用对象为血小板低于50×109.L-1且有必要升高血小板的患者。现对其药理作用、药动学、临床评价及不良反应等做一综述。
Recombinant human thrombopoietin is a specific platelet stimulating factor. It directly acts on the hemopoietic stem cells in bone marrow, specifically regulates thrombocytopoiesis at each stage, and increases platelet counts. It can be used in the treatment of thrombocytopenia after chemotherapy in the entity tumor patients whose platelet count is less than 50×109·L^-1 In this review, its pharmacological mechanism, pharmacokinetics, clinical evaluation and safety profile were summarized.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2008年第3期254-258,共5页
Chinese Journal of New Drugs
